VBL Therapeutics to Report Fiscal 2017 Results on March 15
March 09 2018 - 8:00AM
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced that it
will host a conference call and live audio webcast on Thursday,
March 15 at 8:30am Eastern Time to report fiscal year ended
December 31, 2017 financial results.
Thursday, March 15th @ 8:30am Eastern
Time |
|
Domestic: |
877-222-6394 |
|
International: |
703-925-2702 |
|
Conference ID: |
7392936 |
|
Webcast: |
https://edge.media-server.com/m6/p/y3srj89d |
|
|
|
|
Replays, Available
through March 29th: |
|
|
Domestic: |
855-859-2056 |
|
International: |
404-537-3406 |
|
Conference ID: |
7392936 |
|
About VBL Vascular Biogenics Ltd.,
operating as VBL Therapeutics, is a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class treatments for cancer. The
Company’s lead oncology product candidate, ofranergene obadenovec
(VB-111), is a first-in-class, targeted anti-cancer gene-therapy
agent that is positioned to treat a wide range of solid tumors. It
is conveniently administered as an IV infusion once every two
months. It has been observed to be well-tolerated in >300 cancer
patients and demonstrated efficacy signals in an “all comers” Phase
1 trial as well as in three tumor-specific Phase 2 studies.
Ofranergene obadenovec is currently being studied in a Phase 3
trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
MEDIA CONTACT:Matt Middleman, M.D.LifeSci
Public Relationsmatt@lifescipublicrelations.com(646) 627-8384
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024